Inactive Instrument

Almirall SA Share Price CBOE EUROPE EQUITIES

Equities

ES0157097017

Pharmaceuticals

End-of-day quote CBOE EUROPE EQUITIES
- EUR - Intraday chart for Almirall SA

Financials

Sales 2024 * 975M 1.04B 87.16B Sales 2025 * 1.08B 1.16B 96.81B Capitalization 2.06B 2.21B 185B
Net income 2024 * 21M 22.48M 1.88B Net income 2025 * 57M 61M 5.1B EV / Sales 2024 * 2.14 x
Net Debt 2024 * 17.76M 19.01M 1.59B Net cash position 2025 * 73.5M 78.66M 6.57B EV / Sales 2025 * 1.84 x
P/E ratio 2024 *
93.9 x
P/E ratio 2025 *
36.2 x
Employees -
Yield 2024 *
1.59%
Yield 2025 *
1.81%
Free-Float 36.02%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer - 25/14/25
Director of Finance/CFO 54 11/19/11
Chief Tech/Sci/R&D Officer - 07/21/07
Members of the board TitleAgeSince
Director/Board Member - 01/16/01
Director/Board Member 65 01/20/01
Director/Board Member 65 01/19/01
More insiders
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
Calendar
More about the company